Literature DB >> 22085916

Congenital parasitic infections: a review.

Yves Carlier1, Carine Truyens, Philippe Deloron, François Peyron.   

Abstract

This review defines the concepts of maternal-fetal (congenital) and vertical transmissions (mother-to-child) of pathogens and specifies the human parasites susceptible to be congenitally transferred. It highlights the epidemiological features of this transmission mode for the three main congenital parasitic infections due to Toxoplasma gondii, Trypanosoma cruzi and Plasmodium sp. Information on the possible maternal-fetal routes of transmission, the placental responses to infection and timing of parasite transmission are synthesized and compared. The factors susceptible to be involved in parasite transmission and development of congenital parasitic diseases, such as the parasite genotypes, the maternal co-infections and parasitic load, the immunological features of pregnant women and the capacity of some fetuses/neonates to overcome their immunological immaturity to mount an immune response against the transmitted parasites are also discussed and compared. Analysis of clinical data indicates that parasitic congenital infections are often asymptomatic, whereas symptomatic newborns generally display non-specific symptoms. The long-term consequences of congenital infections are also mentioned, such as the imprinting of neonatal immune system and the possible trans-generational transmission. The detection of infection in pregnant women is mainly based on standard serological or parasitological investigations. Amniocentesis and cordocentesis can be used for the detection of some fetal infections. The neonatal infection can be assessed using parasitological, molecular or immunological methods; the place of PCR in such neonatal diagnosis is discussed. When such laboratory diagnosis is not possible at birth or in the first weeks of life, standard serological investigations can also be performed 8-10 months after birth, to avoid detection of maternal transmitted antibodies. The specific aspects of treatment of T. gondii, T. cruzi and Plasmodium congenital infections are mentioned. The possibilities of primary and secondary prophylaxes, as well as the available WHO corresponding recommendations are also presented.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22085916     DOI: 10.1016/j.actatropica.2011.10.018

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  52 in total

1.  Human Immunoglobulin Heavy Gamma Chain Polymorphisms: Molecular Confirmation Of Proteomic Assessment.

Authors:  Magalie Dambrun; Célia Dechavanne; Alexandra Emmanuel; Florentin Aussenac; Marjorie Leduc; Chiara Giangrande; Joëlle Vinh; Jean-Michel Dugoujon; Marie-Paule Lefranc; François Guillonneau; Florence Migot-Nabias
Journal:  Mol Cell Proteomics       Date:  2017-03-06       Impact factor: 5.911

2.  The evolution of mutation rate in an antagonistic coevolutionary model with maternal transmission of parasites.

Authors:  Philip B Greenspoon; Leithen K M'Gonigle
Journal:  Proc Biol Sci       Date:  2013-05-01       Impact factor: 5.349

Review 3.  Toxoplasma gondii Hsp90: potential roles in essential cellular processes of the parasite.

Authors:  Sergio O Angel; Maria J Figueras; Maria L Alomar; Pablo C Echeverria; Bin Deng
Journal:  Parasitology       Date:  2014-02-21       Impact factor: 3.234

4.  Comparison of nested polymerase chain reaction and microscopy as diagnostic tools in congenital malaria: a study at tjark corneile hillers hospital maumere, indonesia.

Authors:  Natalia Erica Jahja; Irene Ratridewi Huwae; Mario B Nara; Adinda Harley; Tarina Widaningrum; Loeki Enggar Fitri
Journal:  Malays J Med Sci       Date:  2014 Sep-Oct

5.  Host-parasite interactions and the evolution of nonrandom mating.

Authors:  Philip B Greenspoon; Leithen K M'Gonigle
Journal:  Evolution       Date:  2014-11-20       Impact factor: 3.694

6.  Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.

Authors:  Rama Subba Rao Vidadala; Kasey L Rivas; Kayode K Ojo; Matthew A Hulverson; Jennifer A Zambriski; Igor Bruzual; Tracey L Schultz; Wenlin Huang; Zhongsheng Zhang; Suzanne Scheele; Amy E DeRocher; Ryan Choi; Lynn K Barrett; Latha Kallur Siddaramaiah; Wim G J Hol; Erkang Fan; Ethan A Merritt; Marilyn Parsons; Gail Freiberg; Kennan Marsh; Dale J Kempf; Vern B Carruthers; Nina Isoherranen; J Stone Doggett; Wesley C Van Voorhis; Dustin J Maly
Journal:  J Med Chem       Date:  2016-07-01       Impact factor: 7.446

Review 7.  Strategies for Prevention and Treatment of Trichomonas vaginalis Infections.

Authors:  Kawthar Bouchemal; Christian Bories; Philippe M Loiseau
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

8.  Trypanosoma cruzi experimental congenital transmission associated with TcV and TcI subpatent maternal parasitemia.

Authors:  Sandra Maria Alkmim-Oliveira; André Guilherme Costa-Martins; Henrique Borges Kappel; Dalmo Correia; Luis Eduardo Ramirez; Eliane Lages-Silva
Journal:  Parasitol Res       Date:  2012-11-18       Impact factor: 2.289

9.  Seroprevalence of Trypanosoma cruzi among mothers and children in rural Mayan communities and associated reproductive outcomes.

Authors:  Rubi Gamboa-León; Claudia Ramirez-Gonzalez; Freddy S Pacheco-Tucuch; Matthew O'Shea; Kathryn Rosecrans; Julia Pippitt; Eric Dumonteil; Pierre Buekens
Journal:  Am J Trop Med Hyg       Date:  2014-06-16       Impact factor: 2.345

10.  Toxoplasma seroconversion with negative or transient immunoglobulin M in pregnant women: myth or reality? A French multicenter retrospective study.

Authors:  H Fricker-Hidalgo; B Cimon; C Chemla; M L Darde; L Delhaes; C L'ollivier; N Godineau; S Houze; L Paris; D Quinio; F Robert-Gangneux; O Villard; I Villena; E Candolfi; H Pelloux
Journal:  J Clin Microbiol       Date:  2013-04-24       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.